Answers are grounded in this paper and cite their sources.
Molecular structure, revealed by crystallography, cryo-electron microscopy, imaging, and prediction, remains foundational to biology and drug design, yet function also depends on how structures flex, adapt, and interact. Proteins and RNA populate alternative conformations and binding states, while chromatin, membranes, glycans, metabolites, water, ions, and biominerals vary in composition and organization. This narrative review treats form and function as interdependent properties of molecular ensembles: structure constrains which states are accessible, whereas regulatory inputs, partners, and cellular environments determine which states are occupied, exchanged, and used. Without assuming a shared physical mechanism, we compare these systems and propose a cross-class evidence map that links each claimed state variable to its regulatory input, matched measurement, causal test, and organismal or clinical outcome. Examples from cancer, neurodegeneration, infection, and metabolic disease show how specific states become dysregulated, and why restored binding, assembly, or imaging readouts need not indicate functional recovery. Therapies are compared by primary mode of action—direct state modulation, target-abundance reduction, or genetic and RNA-level correction—with clinical successes, failures, and safety limits reported separately. The synthesis identifies where measurement methods must advance to resolve interrelated ensembles in native contexts and to determine when targeting them yields meaningful patient benefit.
No takes yet. Share an insight, caveat, or question.
Patarca et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: